[Special Stock] Yuhan Yanghaeng Hits 52-Week High... Partners with Progen for New Drug Research Agreement

Development of Immune Checkpoint Dual Antibodies Raises Expectations for Performance Improvement
"Aiming to Secure a Globally Competitive New Drug Pipeline"

Yuhan Corporation is showing strong performance. It appears to be influenced by the news of signing a project related to Progen and new drug development. In particular, the news of developing an immune-oncology bispecific antibody is raising expectations for improved earnings.

As of 11:28 AM on the 5th, Yuhan Corporation is trading at 89,900 KRW, up 12.52% (10,000 KRW) compared to the previous day. It has broken its 52-week high after 4 trading days. The previous 52-week high was 83,400 KRW on the 1st.

Yuhan Corporation signed an innovative new drug joint research and development contract with Progen the day before. The first project selected was the immune-oncology bispecific antibody. The immune-oncology bispecific antibody is known as an innovative cancer treatment that can simultaneously recognize and bind to two targets.

Yuhan Corporation is also gaining attention as a company related to vaccines, diagnostic reagents, and quarantine supplies. It belongs to related industries along with Daesung Microbiological Labs, Shinpung Pharmaceutical, and EagleVet, and is particularly positively affected by the increased demand for vaccines and quarantine products.

Jo Wook-je, CEO of Yuhan Corporation, stated, "Through continuous technology exchange and cooperation with Progen, we will secure an innovative new drug pipeline with global competitiveness."

This content was produced with the assistance of AI translation services.